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Abstract
Objective: The aim of the present study was to estimate the dose of buprenorphine and its primary metabolite
norbuprenorphine that a breastfed infant would receive during maternal maintenance treatment with bupre-
norphine.
Study Design: Seven pregnant opioid-dependent women taking buprenorphine (median, 7 mg/day; range, 2.4–
24 mg) and who intended to breastfeed were recruited. After lactation was established, several milk samples
were collected from each subject over a 24-hour dose interval, and buprenorphine and norbuprenorphine
concentrations were measured by liquid chromatography–tandem mass spectrometry. The average concentra-
tion (Cavg) across the dose interval was estimated as for both buprenorphine and norbuprenorphine (as bu-
prenorphine equivalents). Absolute infant dose (AID), defined as Cavg · daily milk intake, and relative infant
dose (RID), defined as 100 · AID/weight-adjusted maternal daily dose, via milk were calculated, assuming a
milk intake of 0.15 L/kg/day. The infant’s health and progress were assessed directly and by questionnaire on
the study day.
Results: Mean (95% confidence interval) norbuprenorphine concentration in milk and AID values (1.94 [0.79–
3.08] lg/L and 0.29 [0.12–0.46] lg/kg/day, respectively) were approximately half those for buprenorphine
(3.65[1.61–5.7] lg/L and 0.55 [0.24–0.85] lg/kg/day, respectively). Similarly, the mean RID values were 0.18%
(0.11–0.25%) for norbuprenorphine and 0.38% (0.23–0.53%) for buprenorphine. The breastfed infants showed no
adverse effects, were all in good health, and were progressing as expected.
Conclusion: Thus the dose of buprenorphine and norbuprenorphine received via milk is unlikely to cause any
acute adverse effects in the breastfed infant.
Introduction
Buprenorphine is a partial opiate agonist used formaintenance treatment of adults, including pregnant
women addicted to opiates. It is initially metabolized by N-
dealkylation to norbuprenorphine, primarily by hepatic cy-
tochrome P450 3A4.1 Subsequently, both compounds are
conjugated by uridine diphosphoglucoronosyl transferases
(UGTs), with UGT1A1 and UGT2B7 primarily conjugating
buprenorphine2,3 and UGT1A1 and UGT1A3 conjugating
norbuprenorphine.4 In the context of this study, norbupre-
norphine is of interest as rodent studies suggest that it has
approximately 25% of the analgesic activity5 and approxi-
mately 10 times the respiratory depressant activity of bupre-
norphine.6
The aim of the present study was to estimate the dose of
buprenorphine and its primary metabolite norbuprenorphine
that a breastfed infant would receive during maternal main-
tenance treatment with buprenorphine. When we com-
menced this study in 2008, there was one published case
report suggesting that infant exposure to buprenorphine and
norbuprenorphine via milk was very low,7 and since then
1Pharmacology and Anaesthesiology Unit, School of Medicine and Pharmacology, University of Western Australia, Crawley, Western
Australia, Australia.
2Clinical Pharmacology and Toxicology Laboratory, Path West Laboratory Medicine, Nedlands, Western Australia, Australia.
3School of Nursing and Midwifery, Faculty of Health Sciences, Curtin University of Technology, Bentley, Perth, Western Australia, Australia.
4School of Women’s and Infants’ Health, University of Western Australia, Crawley, Western Australia, Australia.
5King Edward Memorial Hospital, Women and Newborn Health Services, Subiaco, Western Australia, Australia.
BREASTFEEDING MEDICINE
Volume 7, Number 4, 2012
ª Mary Ann Liebert, Inc.
DOI: 10.1089/bfm.2011.0096
269
there has been a second report documenting similar low-dose
exposure in six mother–infant nursing pairs.8 Our study es-
sentially doubles the database available for assessment of the
safety of buprenorphine use during lactation.
Subjects and Methods
Seven pregnant opioid-dependent women participating in
a buprenorphine substitution treatment program were re-
cruited in their third trimester from the Women and Newborn
Drug and Alcohol Service antenatal clinic at the King Edward
Memorial Hospital, Subiaco, WA, Australia. The women gave
written informed consent to their participation in the study
according to protocols approved by the Women and New-
born Services Ethics Committee (protocol number 1552/EW)
and were intending to breastfeed. The women were visited at
home 3 weeks after birth and provided with a sample col-
lection kit consisting of labeled sample tubes, a data collection
sheet, and information forms. The mothers were educated on
sample collection and labeling procedures by the research
assistant. The infants were weighed at this visit. Most of the
women were taking buprenorphine daily, but one was on a
twice-daily schedule. This mother arranged with her pre-
scribing doctor to have her buprenorphine adjusted to daily to
reduce the expressing commitment to 24 hours. The research
assistant visited the women at home when advised of collec-
tion being completed to further check on the infant’s well-
being, quality control sample collection, and documentation
and to transport samples to the laboratory. The research as-
sistant also recorded data on sleep patterns, advice provided
on breastfeeding, and general impressions of the infant, mo-
ther, and home. Identified problems and referrals were also
recorded. A 2-page questionnaire was delivered to the mother
requesting information on the commencement of breastfeed-
ing and duration of breastfeeding. Mothers were asked to rate
their breastfeeding pattern as ‘‘all breastfeeds,’’ ‘‘nearly all
breastfeeds,’’ ‘‘about half are breastfeeds,’’ or ‘‘only one
breastfeed per day.’’ If mothers had ceased breastfeeding they
were asked for the reason, and this was recorded in the
questionnaire. The questionnaire also asked about any phar-
macological treatment required for their baby. At this visit the
women were paid $80 for their involvement in the study. Data
were obtained on maternal age, weight, birth, and bupre-
norphine dose. Infant data included gestational age, 1-minute
and 5-minute Apgar scores, evidence of the neonatal absti-
nence syndrome (NAS) in hospital and at follow-up, birth
weight, and weight at follow-up and breastfeeding. The
Modified Finnegan Scale was used to assess severity of NAS.9
Studies started with the daily sublingual buprenorphine
(Subutex, Reckitt Benckiser, West Ryde, Australia) dose (0.4-,
2-, or 8-mg tablets as required) at around 8:00 a.m., and each
woman provided up to 12 samples of milk (by manual or
pump extraction) over the next 24 hours. The first sample was
taken immediately prior to the morning dose, and the last was
obtained immediately prior to the end of the 24-hour dose
interval. During the study day, milk samples (4 mL; approxi-
mately 50% fore-milk and 50% hind-milk mixed together)
were collected each time the women fed their infants. If pos-
sible, at one or more of the feeds the fore-milk and hind-milk
samples (2 mL each) were collected separately so that differ-
ences in drug concentration across a feed could be assessed. A
urine sample was also collected on the study day and screened
for amphetamines, benzodiazepines, cocaine metabolites,
opiates (using Cedia homogeneous immunoassay kits
[Microgenics Diagnostics Pty. Ltd., Auburn, NSW, Australia]),
and tetrahydrocannabinol (THC) carboxylic acid (DRI assay
kit, Thermo Fisher Scientific, Clinical Diagnostics Division,
North Ryde, NSW, Australia) on an Olympus AU2700 Auto-
analyzer (Beckman Coulter, Mishima, Japan), according to the
manufacturer’s protocols.
Reference standards of buprenorphine, buprenorphine-d4,
norbuprenorphine, and norbuprenorphine-d3 were obtained
from Cerilliant Corp. (Round Rock, TX). Buprenorphine and
norbuprenorphine in milk (1 mL) were quantified by an ultra-
performance liquid chromatography (UPLC)–electrospray
interface–tandem mass spectrometry (MS/MS) assay. Un-
known samples (1 mL each) and standards (1 mL each con-
taining 0.0, 0.1, 0.25, 1, 2, 5, and 10 lg/L buprenorphine
and norbuprenorphine) were spiked with 5 ng each of
buprenorphine-d4 and norbuprenorphine-d3, alkalinized with
1 mL of 2% (wt/vol) Na2B4O7, and extracted into 10 mL of
diethyl ether (catalog number 1.00926.5000, Merck Chemicals
Australia, Kilsyth, VIC, Australia) by shaking vigorously for 5
minutes. After centrifugation at 1,500 g for 5 minutes, the
diethyl ether layer was back-extracted into 1.5 mL of 0.05 M
HCl by shaking for 2 minutes. After centrifugation as above,
the HCl layer was aspirated, mixed with 1 mL of 2 M
NH4COOCH3 (adjusted to pH 9.2), and extracted into 10 mL
of diethyl ether as above. After centrifugation, the diethyl
ether layer was evaporated to dryness under a stream of N2
and reconstituted in 0.1 mL of the mobile phase, and 7-lL
aliquots were injected onto the UPLC-MS/MS system. Assays
used an Agilent Zorbax Eclipse XDB-C18 narrow-bore (2.1- ·
150-mm; particle size, 5 lm) column (Agilent Technologies
Australia, Forest Hill, VIC, Australia) with a mobile phase of
30% (vol/vol) CH3CN, 30% (vol/vol) methanol, and 40%
(vol/vol) 4 mM aqueous NH4COOCH3 (previously adjusted
to pH 3.2 with acetic acid) and pump rate of 0.25 mL/minutes.
Analyses were performed using a Waters Acquity UPLC ap-
paratus (Waters Corp., Milford, MA) coupled to a Waters
Quattro Premier XE MS/MS instrument running in electro-
spray interface (electrospray ionization positive) mode. Un-
der these conditions, buprenorphine and norbuprenorphine
had retention times of 1.6 and 2.3 minutes, respectively. Data
acquisition and processing were carried out using the Waters
Masslynx and Quanlynx software. The m/z transitions used
were from 468 to 468 for buprenorphine, 472 to 472 for bu-
prenorphine-d4, 414 to 414 for norbuprenorphine, and 417 to
417 for norbuprenorphine-d3.
10 For milk the intra-day relative
SD (RSD) values at 0.25 lg/L and 10 lg/L were 6.4% and
7.4%, respectively, for buprenorphine and 3.7% and 1.8%,
respectively, for norbuprenorphine (n = 5). Similarly, for milk
the inter-day RSDs at 0.25 lg/L and 10 lg/L were 6.1% and
7.8%, respectively, for buprenorphine and 3.7% and 2.6%,
respectively, for norbuprenorphine. The limit of quantifica-
tion (RSD < 20%) for both analytes in milk was 0.1 lg/L.
Correlation coefficients for the individual standard curves
were 0.997 or better, and no interferences were found in blank
milk samples. Quality control sample(s) were included with
each batch of assays and had to be within – 15% of the nom-
inal value for the batch to be accepted.
The milk concentration–time datasets were subjected to
noncompartmental pharmacokinetic analysis using Topfit
version 2.011 to calculate area under the curve (AUC) for 0–24
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hours and average concentration (Cavg), defined as AUC for
0–24 hours/24, across the 24-hour dose interval. All norbu-
prenorphine AUC and Cavg data have been reported as ‘‘bu-
prenorphine equivalents’’ after multiplying the raw
concentration data from UPLC-MS/MS by the molecular
weight ratio of buprenorphine/norbuprenorphine (467.6/
413.6 = 1.1306). Milk creamatocrit was measured as previ-
ously described,12 and absolute infant dose (AID), defined as
Cavg · daily milk intake, and relative infant dose (RID), de-
fined as 100 · AID/weight-adjusted maternal daily dose, via
milk were calculated according to the method of Bennett,13
assuming a milk intake of 0.15 L/kg/day. Differences in
median milk buprenorphine (lg/L), norbuprenorphine (lg/
L), and creamatocrit (%) between paired fore-milk and hind-
milk samples were examined using Wilcoxon’s Rank Signed
test (SigmaPlot version 11.0, Systat Software Inc., San Jose,
CA). Results are summarized as mean (95% confidence in-
terval or range) or median (range or interquartile range) as
appropriate.
Results
The characteristics of the mothers and their infants are
summarized in Tables 1 and 2. The mothers’ mean age was 31
years, with a mean weight of 72.8 kg. Three births were by
cesarean section, whereas the others were spontaneous vagi-
nal deliveries. Median sublingual buprenorphine dose was
7 mg, with a range from 2.4 to 24 mg once daily. The urine
drug screen conducted on the study day revealed that
two subjects were negative for all drugs, whereas another two
were negative for amphetamines, opiates, and cocaine, two
were positive for benzodiazepines, and four were positive for
THC. Their infants were four girls and three boys, with nor-
mal Apgar scores. Three infants required transfer to a special
Level 2 nursery. Four infants had NAS scores of 9 and above,
but only one required pharmacological treatment with mor-
phine. On discharge from the hospital, five infants were ex-
clusively breastfed, and two were supplemented with
formula. At follow-up two had NAS scores of 2, and one had a
score of 8. The mean age and weight were 1.12 months and
4.32 kg, respectively, on the study day. All were tracking ac-
cording to their expected weight-for-age percentiles from
birth to the study day and were exhibiting normal sleep pat-
terns.14 All mothers indicated that their infants were pro-
gressing well at the time of study, although one mother
expressed concern about loose stools, and a second mother
expressed concern about constipation. One infant was still
being treated with morphine at 5 weeks of age. All mothers
were coping well and confident with mothercrafting. Four
mothers reported they were exclusively breastfeeding at fol-
low-up, whereas two were supplementing with formula but
reported they were breastfeeding for the majority of feeds.
One mother reported she was breastfeeding approximately
half of all feeds. However, this mother received help with
lactation and was breastfeeding for the majority of feeds some
weeks later.
The concentrations of buprenorphine and norbuprenor-
phine (raw data from UPLC-MS/MS) in milk samples col-
lected for the individual mothers across the 24-hour dose
interval are shown in Figure 1A and B, respectively. Table 3
summarizes the Cavg milk concentrations achieved as well as
the AID and RID for buprenorphine and norbuprenorphine
(as buprenorphine equivalents; see Subjects and Methods).
Mean norbuprenorphine Cavg in milk (1.94 lg/L) and its
mean AID (0.29 lg/kg/day) values were approximately half
those for buprenorphine (3.65 lg/L and 0.55 lg/kg/day, re-
spectively). Similarly, even after normalization to maternal
dose, the mean RID values were 0.18% for norbuprenorphine
and 0.38% for buprenorphine. When buprenorphine and
norbuprenorphine (as buprenorphine equivalents) Cavg milk
concentrations were summed and normalized per 10 mg of
daily buprenorphine dose, the mean (95% confidence inter-
val) data were 6.0 (4.9–7.1) lg · day/L · 10 mg.
The mean maximum concentration (Cmax) of buprenor-
phine in milk was 9.1 (4.8–13.4) lg/L at 4.2 (2.1–6.3) hours
after dosing, whereas for norbuprenorphine (as buprenor-
phine equivalents) the maximum concentration was 2.1 (0.9–
3.3) lg/L at 4.0 (2.1–5.8) hours after dosing. If the later Cmax
concentrations are used for infant dose assessment, one ob-
tains AIDs of 1.4 (0.7–2) lg/kg/day and 0.32 (0.14–0.5) lg/
kg/day for buprenorphine and norbuprenorphine, respec-
tively, and RIDs of 1.21 (0.66–1.75%) and 0.25 (0.19–0.3%) for
buprenorphine and norbuprenorphine, respectively.
Four patients contributed data from which drug concen-
trations in paired fore-milk and hind-milk samples could be
compared using the Wilcoxon Rank Signed test (paired
sample analysis, n = 16). Subjects 2 and 6 contributed five
samples each, subject 3 contributed four samples, and subject
4 contributed two samples. For buprenorphine, the median
(interquartile range) concentration (1.8 lg/L [1.3–6.2 lg/L])
in fore-milk was not significantly different from that (1.9 lg/L
[1.6–6.1 lg/L]) in hind-milk. Similarly, for norbuprenorphine,
Table 1. Maternal Characteristics
Study number Age (years) Weight (kg) Birth Buprenorphine dose (mg/day) Drug screen resulta
1 27.4 62.4 SVD 10 THC
2 31.8 68 CS 10 Negative
3 29.7 100.4 SVD 24 Benzodiazepines
4 26.8 66.3 CS 6 THC, benzodiazepines
5 34.7 70.4 CS 2.4 Negative
6 35.9 68 SVD 6 THC
7 30.9 73.9 SVD 7 THC
Mean (range) 31 (27.4–35.9) 72.8 (62.4–100.4) 7 (2.4–24)b
aScreen by immunoassay for amphetamines, benzodiazepines, cocaine, opiates, and tetrahydrocannabinol (THC).
bMedian (range).
CS, delivery by cesarean section; SVD, spontaneous vaginal delivery.
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the concentration (2.1 lg/L [0.6–3.2 lg/L]) in fore-milk also
was not significantly different from that (2.1 lg/L [0.7–4.2 lg/
L]) in hind-milk. However, there was also no significant
change in median (interquartile range) creamatocrit values
from fore-milk samples (6.3% [3.7–6.7%]) compared with
hind-milk samples (6.2% [5.6–7.1%]).
Discussion
The urine drug screen results indicated that all subjects
were, apart from buprenorphine, opiate-free. Benzodiaze-
pines (not prescribed) were detected in two subjects, and four
had used THC. In our experience, this pattern of drug use is
typical of opiate-dependent mothers maintained on bupre-
norphine.
Drug transfer into milk occurs primarily by passive diffu-
sion, and lipid solubility of the drug and co-transfer in milk
lipid are important factors in this process.15 The lack of any
increase in buprenorphine or norbuprenorphine concentra-
tions in hind-milk versus fore-milk was unexpected. Never-
theless, our opportunity to detect any such increase was
limited by the similarity of the fat content (creamatocrit) in the
fore-milk versus hind-milk samples. We have no explanation
for the lack of increase of creamatocrit in hind-milk samples.
There was wide inter-subject variability in milk Cavg. This































































































































































































































































































































































































































































































































































FIG. 1. (A) Buprenorphine and (B) norbuprenorphine
concentrations in milk versus time after dose for each of the
seven studies. All concentrations are reported as raw data
measured by ultra-performance liquid chromatography–
tandem mass spectrometry.
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11-fold for norbuprenorphine (range, 0.45–4.96 lg/L) as il-
lustrated in Figure 1 and the corresponding data in Table 2.
Nevertheless, when the Cavg data were expressed per 10-mg
buprenorphine dose (mean [range] of 4.0 [1.75–6.75] lg ·
day/L · 10 mg for buprenorphine and 2.0 [2.44–0.99] lg ·
day/L · 10 mg for norbuprenorphine), it is clear from the re-
duced spread in the dose-normalized data (3.9-fold for bu-
prenorphine and 2.5-fold for norbuprenorphine) that dose
accounts for a large proportion of inter-subject variability in
milk Cavg. The residual variability in milk Cavg presumably
represents the true between-subject variability plus that due
to unexplained sources. A limitation of our study is the use of
an estimated value of 0.15 L/kg/day for infant milk intake,
which may have reduced both inter-subject variability in both
measured drug concentrations and in estimates of infant dose.
The mean AID of 0.55 lg/kg/day for buprenorphine was
almost twice that of 0.29 lg/kg/day for norbuprenorphine.
However, there is no pediatric dose available for comparison,
as use of buprenorphine in children is not recommended be-
cause of lack of clinical safety and efficacy data in patients
under 18 years of age. The mean RID values of 0.38% and
0.18% for buprenorphine and norbuprenorphine, respec-
tively, are well below the 10% limit13 below which breast-
feeding is acceptable for many drugs. Our data are similar to
those of Lindemalm et al.,8 who reported a median AID of
0.42 lg/kg/day and 0.33 lg/kg/day and median RID of 0.2%
and 0.12% for buprenorphine and norbuprenorphine, re-
spectively, in six mother–infant pairs. This confirmation is
encouraging, given that the infants in the latter study were
only 5–8 days old and were studied in a maternity ward
where it was possible to measure the daiIy milk intake for
each infant and thus individualize the calculation of infant
dose. In addition, our data also compare with the AIDs of
0.77 lg/kg/day for buprenorphine and 0.08 lg/kg/day for
norbuprenorphine and RIDs 1.3% for buprenorphine and
0.14% for norbuprenorphine, which can be calculated (as-
suming infant weight of 4.25 kg and a maternal weight of
70 kg) from the dose and drug concentration data from the
single case reported by Marquet et al.7 The buprenorphine
and norbuprenorphine concentrations we measured in milk
were also within the range reported in one subject over a 4-
day period.10 However, these authors did not report infant
dose estimates.
When Cmax concentrations of buprenorphine or norbupre-
norphine in milk were used to calculate AID and RID, as the
worst case scenario for potential infant exposure, mean AID
for buprenorphine increased 2.5-fold to 1.4 lg/kg/day, and
mean RID increased 3.2-fold to 1.2%; AID and RID for nor-
buprenorphine were virtually unchanged. The increased ex-
posure to buprenorphine (assessed as RID) at the time of Cmax
is still well within the usual safety margin (exposure < 10%). It
is our view that the use of Cavg in calculation of infant dose
best reflects infant exposure across the whole dose interval.
Our data show that RIDs (calculated using Cavg) for both
buprenorphine and norbuprenorphine combined are less than
1% of the maternal weight-adjusted dose and support the in-
ference that this amount of exposure by mouth is unlikely to be
a cause of adverse effects in the breastfed infants. In agreement
with a previous study8 the limited assessment of the breastfed
infants in our study found no drug-related adverse effects and
satisfactory developmental progress. However, we note that
only four of the seven infants were exclusively breastfed, as this
would limit our ability to detect adverse effects. Our study
essentially doubles the database available for assessing the
infant dose of buprenorphine use during lactation. There are
also several observational short-term studies showing that
breastfeeding while taking buprenorphine as a maintenance
treatment causes no adverse effects in the breastfed infant, al-
though a mild abstinence syndrome is sometimes seen in the
first few weeks after birth.7,16–20 Nevertheless, the amounts of
buprenorphine and norbuprenorphine in milk are not suffi-
cient to prevent withdrawal.7,21
Conclusions
We conclude that the dose of buprenorphine and norbu-
prenorphine that a breastfeeding infant receives via milk is
generally less than 1% of the weight-adjusted maternal dose
and unlikely to cause any acute adverse effects in the infant.
The possibility that long-term developmental outcomes might
be affected by infant exposure to these drugs in milk cannot be
excluded, and future studies on this topic are desirable.
Nevertheless, mothers receiving sublingual buprenorphine
maintenance treatment should be encouraged to breastfeed as
there are many benefits of breastmilk for their infants.22
Regular clinical assessment of infants in this population is
Table 3. Values for Average Concentration in Milk, Absolute Infant Dose, and Relative Infant Dose
of Buprenorphine and Norbuprenorphine
Milk Cavg (lg/L) over 24 hours Absolute infant dose (lg/kg/day) Relative infant dose
b
Study number Buprenorphine Norbuprenorphinea Buprenorphine Norbuprenorphinea Buprenorphine Norbuprenorphinea
1 6.75 2.34 1.01 0.35 0.63 0.22
2 1.75 2.44 0.26 0.37 0.18 0.25
3 8.27 4.96 1.24 0.74 0.52 0.31
4 2.3 1.59 0.35 0.24 0.04 0.03
5 0.83 0.45 0.12 0.07 0.37 0.20
6 2.9 0.60 0.44 0.09 0.49 0.10
7 2.76 1.18 0.41 0.18 0.44 0.19
Mean (95% CI) 3.65 (1.61–5.7) 1.94 (0.79–3.08) 0.55 (0.24–0.85) 0.29 (0.12–0.46) 0.38 (0.23–0.53) 0.18 (0.11–0.25)
aExpressed as buprenorphine equivalents.
bEqual to absolute infant dose as a percentage of daily weight-adjusted maternal dose (which was calculated in lg/kg/day from data in
Table 1).
Cavg, average concentration, CI, confidence interval.
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recommended to ensure that any adverse effects to prescribed
medications and/or other drugs used by their mothers are
minimized.
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